The mitochondrial (also called intrinsic, stress or BCL-2 regulated) apoptotic pathway is regulated by members of the BCL-2 family.^[@bib1]^ This protein family can be divided into pro-survival (A1, MCL-1, BCL-2, BCL-XL and BCL-W) and pro-apoptotic members. The latter can be further sub-divided into the BH3-only (BIM, PUMA, BID, BAD, NOXA, HRK, BMF, BIK) and the multi-BH domain members (BAX, BAK and possibly BOK).^[@bib2]^ Pro-survival BCL-2 family members protect cells from dying through binding and neutralizing the pro-apoptotic BCL-2 family members. Upon an apoptotic stimulus, the levels of certain BH3-only proteins increase as a result of transcriptional and/or post-transcriptional upregulation. These BH3-only proteins activate the multi-domain members BAX and BAK either directly, or indirectly through neutralizing the pro-survival BCL-2 family members.^[@bib3],[@bib4]^ Activated BAX and BAK oligomerize and form pores into the outer mitochondrial membrane, leading to the release of apoptogenic factors, such as cytochrome *c*, provoking the activation of the so-called caspase cascade with subsequent demolition of the cell.^[@bib3]^

BIM is a critical initiator of the mitochondrial apoptotic pathway, particularly in hematopoietic cells.^[@bib5]^ During B- and T-cell development, BIM activity is required to eliminate autoreactive lymphocytes.^[@bib6],[@bib7]^ Constitutive loss of BIM (in all cell types) leads to the accumulation of lymphocytes that infiltrate non-hematopoietic organs, such as lungs, kidneys, liver and salivary glands, produce autoantibodies and on a mixed C57BL/6x129SV background this causes severe autoimmune disease resembling systemic lupus erythematosus.^[@bib5]^ BIM is also an important factor in peripheral T-cell apoptosis during the shutdown of an immune response.^[@bib8],[@bib9]^ BIM is a tumor suppressor in mantle cell lymphoma, where the gene is lost,^[@bib10]^ as well as Burkitt\'s lymphoma and renal carcinoma in which the gene is silenced.^[@bib11],[@bib12]^ Loss of BIM renders cells resistant to several pro-apoptotic stimuli, such as withdrawal of growth factors, treatment with calcium ionophores^[@bib5]^ or ER stress.^[@bib13]^

This information about BIM\'s physiological function was derived from the study of a mouse strain in which the *Bim* gene was constitutively inactivated in all cell types.^[@bib5]^ The complete absence of a gene product during the entire life of an animal can lead to phenotypes that are not cell-autonomous and may also lead to compensatory events (for example, upregulation of genes with overlapping function). Therefore techniques have been developed so that a gene of interest can be conditionally inactivated in a tissue-specific and/or temporally controllable manner using the Cre/Lox system.^[@bib14]^ A further refinement of this technique consisted in engineering an inducible Cre recombinase by fusing it with a modified hormone-binding domain of the estrogen receptor (CreER).^[@bib15]^ In the absence of 4-hydroxytamoxifen (4-OHT), the CreER protein is sequestered in an inactive state in the cytosol. Upon administration of 4-OHT, the ER domain of the CreER fusion protein changes conformation, prompting the translocation of the fusion protein into the nucleus where the recombinase can delete DNA sequences flanked by *loxP* sites.^[@bib15]^

We developed a conditional *Bim* allele allowing for temporally and spatially controllable deletion of this critical apoptosis initiator. In addition, we developed a novel strain, which expresses the CreER fusion protein under the control of the pan-hematopoietic *Vav* promoter.^[@bib16]^ We show that the deletion of *Bim* in the adult mouse through activation of the CreER recombinase, using the *Vav-CreER* or the ubiquitously expressed *Rosa-CreER* transgene, caused hematopoietic abnormalities that were similar to those found in the constitutive *Bim* knockout animals. These novel strains (conditional *Bim ko* and *Vav-CreER*) will allow further detailed genetic investigations of cell death and tumourigenesis.

Results
=======

BIM expression and phenotype in mice with floxed *Bim* alleles before and after Cre-mediated recombination
----------------------------------------------------------------------------------------------------------

The BH3-only protein BIM is the most critical initiator of apoptosis in hematopoietic cell development and homeostasis.^[@bib5]^ Mice constitutively deficient for BIM show many abnormalities, including increased white blood cell (WBC) counts, splenomegaly and defects in thymic T-cell selection.^[@bib6]^ As these defects could potentially be affected by the absence of BIM (i) in non-hematopoietic cells or (ii) be dependent on absence of BIM during embryonic development, we decided to generate mice with a conditional *Bim* allele (*Bim*^*fl*^), to allow specific deletion of *Bim* in a time- and/or tissue-specific manner. Coding exons 2, 3 and 4 of *Bim*^[@bib17]^ were flanked by *loxP* sites.^[@bib18]^ As expected, BIM protein expression and hematopoietic cell composition, WBC counts, spleen weights and thymic cell subset distribution, were comparable between *Bim*^*fl/fl*^ and wt mice ([Figure 1](#fig1){ref-type="fig"}). Crossing *Bim*^*fl/fl*^ mice with the *CMV-Cre* deleter strain^[@bib19]^ resulted in the complete loss of BIM protein (*Bim*^*fl/fl*^*/del*; in this strain, Cre is active in the early embryo) ([Figure 1a](#fig1){ref-type="fig"}) and the concomitant increase of WBC counts ([Figure 1b](#fig1){ref-type="fig"}) and spleen weights ([Figure 1c](#fig1){ref-type="fig"}), as well as the altered distribution of thymocyte populations ([Figure 1d](#fig1){ref-type="fig"}). These results demonstrate that (i) the *loxP* sequences do not alter the expression of the BIM protein or its function and (ii) that deletion of the floxed *Bim* allele recapitulates the phenotype observed in the constitutive *Bim* knockout mice.

Induced deletion of *Bim* in adult mice results in phenotypic alterations similar to those observed in constitutive *Bim* knockout mice
---------------------------------------------------------------------------------------------------------------------------------------

The advantage of a conditional *Bim* allele is the possibility to delete the gene in a temporally and cell type-controllable manner. In order to delete *Bim* at a predetermined time specifically in hematopoietic cells of adult mice, we generated a new transgenic mouse model, in which the tamoxifen-inducible CreERT2 recombinase^[@bib20]^ is expressed under the control of the pan-hematopoietic *Vav* promoter (*Vav-CreER*).^[@bib16]^ To induce *Bim* deletion, 12--20-week-old *Bim*^*fl/fl*^*/Vav-CreER-tg* mice were administered 4-OHT by oral gavage. Four weeks after the treatment, lymph nodes, spleens and thymi were collected from 4-OHT-treated *Bim*^*fl/fl*^, *Vav-CreER*, *Bim*^*fl/fl*^/*Vav-CreER* as well as *Bim*^*−/−*^ mice, and BIM protein levels were measured by intracellular FACS analysis ([Figure 2a](#fig2){ref-type="fig"}). As expected, the BIM protein levels in cells from 4-OHT-treated *Bim*^*fl/fl*^/*Vav-CreER* mice were comparable to those seen in cells from *Bim*^*−/−*^ mice, whereas the presence of the floxed *Bim* (*Bim*^*fl/fl*^) alleles or *CreER* (*Vav-CreER*) transgene had no impact on BIM protein expression when CreERT2 was not activated. This indicated that both *Bim*^*fl*^ alleles had been successfully recombined in *Bim*^*fl/fl*^*/Vav-CreER* hematopoietic cells of tamoxifen-treated mice, explaining why the BIM protein was no longer present in these cells. To further validate the efficiency of the *Vav-CreER* strain, we crossed this strain to mice harboring a floxed allele of *Mcl-1* (*Mcl1*^*fl*^) and treated *Mcl-1*^*fl/+*^*/Vav-CreER-tg* animals with three doses of 4-OHT. As the deletion of the floxed *Mcl-1* allele leads to the expression of the hCD4 reporter,^[@bib21],[@bib22]^ we analyzed the blood of *Mcl-1*^*fl/+*^*/Vav-CreER-tg* two days post treatment by flow cytometry for hCD4 expression ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). This revealed that \~20% of cells had recombined the floxed *Mcl-1* allele within 1 day, validating the utility of the *Vav-CreER* strain.

We also crossed the *Bim*^*fl/fl*^ mice with the *Rosa-CreER* transgenic strain, in which the ubiquitously expressed CreER protein causes the deletion of *Bim* in the entire organism upon 4-OHT treatment.^[@bib23]^ Three to four weeks after 4-OHT treatment, BIM protein levels were examined by intracellular FACS analysis. Cells from the lymph nodes, thymus and spleen of *Bim*^*fl/fl*^*/Rosa-CreER-tg* and *Bim*^*−/−*^ mice showed complete absence of the BIM protein, whereas cells from *Bim*^*fl/fl*^ or *Bim*^*+/+*^*/Rosa-CreER-tg* mice expressed similar levels of BIM protein as the corresponding cells from wt mice ([Figure 2b](#fig2){ref-type="fig"}). As in the *Rosa-CreER-tg* mice, the *CreER* transgene is ubiquitously expressed, we also analyzed the deletion of the BIM protein in non-haematopoietic tissues (liver, kidney) of 4-OHT-treated *Bim*^*fl/fl*^*/Rosa-CreER-tg* mice. As expected, BIM protein was almost undetectable in these organs, whereas treatment of *Rosa-CreER-tg* mice with 4-OHT had no impact on BIM protein levels ([Supplementary Figure 2](#sup1){ref-type="supplementary-material"}).

These results demonstrate that recombination of the floxed *Bim* locus can be successfully achieved in the adult mouse using two different 4-OHT-inducible Cre strains (*Vav-CreER* and *Rosa-CreER*).

As loss of BIM in the entire mouse leads to increased WBC numbers,^[@bib5]^ we analyzed the blood from *Bim*^*fl/fl*^*/Vav-CreER-tg* and *Bim*^*fl/fl*^/*Rosa-CreER-tg* mice 3--4 weeks after 4-OHT treatment ([Figure 3](#fig3){ref-type="fig"}). As anticipated, induced loss of BIM caused an increase in WBC numbers in both *Bim*^*fl/fl*^*/Vav-CreER-tg* and *Bim*^*fl/fl*^*/Rosa-CreER-tg* animals, albeit to different levels ([Figure 3a](#fig3){ref-type="fig"}). The larger increase observed in the *Bim*^*fl/fl*^*/Rosa-CreER-tg* animals probably reflects a faster deletion of *Bim*^*fl*^ alleles in these animals. 4-OHT-treated *Bim*^*fl/fl*^*/Vav-CreER-tg* and *Bim*^*fl/fl*^*/Rosa-CreER-tg* mice also showed similarly abnormal distribution of thymocyte subpopulations, comparable to what is seen in *Bim*^*−/−*^ mice. This is characterised by abnormally high frequencies of double-negative (CD4^−^CD8^−^) and single-positive (CD4^+^CD8^−^, CD4^−^CD8^+^) thymocytes and reduced proportions of double-positive (CD4^+^CD8^+^) thymocytes compared with control (wt) mice ([Figure 3b](#fig3){ref-type="fig"}). This indicates that, although *Bim*^*fl*^ deletion might occur at a slower rate in peripheral lymphoid organs of *Bim*^*fl/fl*^*/Vav-CreER-tg* mice compared with the *Bim*^*fl/fl*^*/Rosa-CreER-tg* animals, *Bim*^*fl*^ recombination in thymocytes (or their precursors) appears to occur at similar rates in both strains.

Induced deletion of *Bim* in the adult mouse protects thymocytes from BIM-dependent apoptotic stimuli
-----------------------------------------------------------------------------------------------------

BIM-deficient thymocytes are resistant to a variety of pro-apoptotic stimuli.^[@bib5]^ We therefore compared the response of thymocytes from *Bim*^*−/−*^, *Bim*^*fl/fl*^*/Vav-CreER-tg*, *Bim*^*fl/fl*^*/Rosa-CreER-tg*, *Bim*^*fl/fl*^, *Vav-CreER* and *Rosa-CreER* mice, which had been treated with 4-OHT four weeks prior to organ isolation, to diverse cytotoxic stimuli. Thymocytes of the different genotypes were cultured in medium (medium; mimicking cytokine withdrawal) or treated with BIM-dependent (Ionomycin=Iono) and BIM-independent (phorbol ester=PMA) apoptotic stimuli ([Figure 4](#fig4){ref-type="fig"}). Although thymocytes from mice of all genotypes were killed at a similar rate when treated with PMA (kills in a PUMA-dependent manner^[@bib24]^), untreated (medium) and Ionomycin-treated thymocytes from 4-OHT-treated *Bim*^*−/−*^, *Bim*^*fl/fl*^*/Vav-CreER-tg* and *Bim*^*fl/fl*^*/Rosa-CreER-tg* mice all showed a marked survival advantage when compared with thymocytes from 4-OHT-treated *Bim*^*fl/fl*^, *Rosa-CreER-tg* and *Vav-CreER-tg* mice. This demonstrates that constitutive or induced deletion of *Bim* in thymocytes leads to a similar resistance to these apoptotic stimuli, and that the observed change in thymocyte distribution is a consequence of the loss of BIM and not due to other abnormalities caused by Cre-mediated recombination.

Discussion
==========

We report here the development of a new *floxed Bim* allele, which allows the deletion of this pro-apoptotic BH3-only protein in a cell type-restricted and temporally controllable manner. Using the well-established *Rosa-CreER* and newly developed *Vav-CreER* transgenic strains, deletion of *Bim* in the adult mice results in the same phenotype as that observed in the constitutive *Bim* knockout mice. It thus appears that the hematopoietic phenotype associated with the constitutive loss of BIM in all cell types reported previously^[@bib5]^ is intrinsic to the hematopoietic system rather than a consequence of an unrecognized developmental defect due to the absence of BIM.

Our studies clearly show that the floxed *Bim* allele is functional and can be efficiently deleted by CreER recombinases. Importantly, these *Bim*^*fl/fl*^ mice have recently been used in two other studies,^[@bib18],[@bib25]^ in which *Bim* was specifically deleted in the regulatory T-cell lineage (Treg) only. This new mouse strain will thus be a valuable tool to further dissect the role of BIM in various cell types.

Importantly, our new *Vav-CreER* transgenic strain showed the same deletion efficiency of the floxed *Bim* alleles 4 weeks after 4-OHT treatment as the very well-characterised and widely used *Rosa-CreER* strain.^[@bib23]^ However, when we tested the loss of BIM protein 5 days after 4-OHT treatment, we observed residual BIM protein in the lymphoid cells from the *Bim*^*fl/fl*^/*Vav-CreER* mice, whereas it was almost completely absent in the cells from the *Bim*^*fl/fl*^/*Rosa-CreER* animals at this time point (data not shown). This indicates that deletion of *Bim*^*fl*^ alleles occurs more rapidly and probably also more efficiently in the *Bim*^*fl/fl*^/*Rosa-CreER* strain than in the *Bim*^*fl/fl*^/*Vav-CreER* strain, possibly because of the lower expression of CreER in the *Vav-CreER* strain.

However, the higher efficiency of Cre-mediated recombination of floxed target genes in the *Rosa-CreER* strain is accompanied by a higher toxicity observed in the animals upon treatment with 4-OHT. Accordingly, treatment of *Rosa-CreER* or *Vav-CreER* transgenic mice with 4-OHT for 5 consecutive days led to substantial destruction of lymphoid organs in the former, whereas these organs remained unaffected in the latter ([Supplementary Figure 3](#sup1){ref-type="supplementary-material"} and data not shown). Both CreER strains are highly efficient at recombining the floxed *Bim* allele and, depending on the experimental requirements, are valuable tools for induced deletion of floxed alleles in mature or developing animals.

A significant leakage in CreER recombinase activity was observed in the *Bim*^*fl/fl*^*/Rosa26-CreER* strain, as tail DNA obtained at weaning showed evidence of Cre-mediated deletion of the floxed *Bim* allele in \~20% of these animals (data not shown). This was never observed in *Bim*^*fl/fl*^*/Vav-CreER-tg* mice. Note that only mice with no evidence of *Bim*^*fl*^ recombination prior to tamoxifen administration were used in this study. Pertinently, we observed no abnormalities in splenic weights and thymocyte sub-population distribution in *Bim*^*fl/fl*^*/Vav-CreER-tg* and *Bim*^*fl/fl*^*/Rosa-CreER-tg* animals prior to 4-OHT treatment (data not shown). We therefore conclude that the occasional leakiness of CreER recombinase activity in the *Rosa-CreER-tg* mice must be limited to embryonic development and that despite this issue (which can be identified by tail DNA analysis), both this inducible CreER mouse strain and the *Vav-CreER-tg* strain are suitable tools for the inducible deletion of floxed genes.

Materials and Methods
=====================

Mice
----

Experiments with mice were conducted according to the guidelines of The Walter and Eliza Hall Institute Animal Ethics Committee. The generation of the conditional *Bim*^*fl*^, *Mcl-1^fl^* and the *RosaCreER* mice, all on a C57BL/6 background, has been described previously.^[@bib18],[@bib21],[@bib26]^ *Vav-CreER* transgenic mice were generated by replacing the hCD4 sequence of the *Vav* hematopoietic vector^[@bib27]^ with the *CreERT2*^[@bib20]^ sequence using *Sfi*1/*Not*1 restriction sites. The *Vav-CreER* construct was linearized with *Hin*dIII before pro-nuclear injection of the DNA into zygotes derived from C57BL/6 mice. Positive offspring were identified by PCR for the genomic integration of the *Vav-CreER* transgene.

To activate the latent CreER recombinase, mice were given 200 mg/kg tamoxifen (Sigma-Aldrich, Rowville, VIC, Australia) in peanut oil/10% ethanol each day for 5 days by oral gavage.^[@bib28]^

Western blotting and WBC analysis
---------------------------------

Cell extracts for western blot analysis were prepared in ONYX lysis buffer (20 mM Tris-HCl pH 7.4, 135 mM NaCl, 1.5 mM MgCl~2~, 1 mM EGTA, 1% Triton X-100, 10% glycerol). Antibodies used include: rat anti-BIM (clones 3C5 and CF7, ENZO Life Sciences,^[@bib29]^ Waterloo, NSW, Australia), mouse anti-*β*-actin (Sigma AC-40, Rowville, VIC, Australia). Horseradish peroxidase-conjugated goat anti-mouse IgG or goat anti-rat IgG antibodies (both from Southern Biotech, Birmingham, AL, USA) served as secondary reagents and the enhanced chemoluminescence (ECL; GE Healthcare, Rydalmere, NSW, Australia) system was used for detection. WBC analysis was performed with an ADVIA blood analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY, USA).

Intracellular immunofluorescent staining of BIM for flow cytometric analysis
----------------------------------------------------------------------------

Cells (1 × 10^6^) from lymph nodes, spleen and thymus were isolated from mice of the indicated genotypes, fixed and permeabilized by suspension in 100 *μ*l of BD Cytofix/Cytoperm (BD Biosciences, San Jose, CA, USA) solution for 20 min on ice. Cells were then washed twice in Perm/Wash buffer (BD Biosciences) and stained with Alexa-647-conjugated BIM antibody (rat, clone \# 3C5,^[@bib29]^ ENZO Life Sciences). Analysis was performed in a FACSalibur (BD Biosciences).

Statistical analysis
--------------------

Statistical comparisons were made using a two-tailed Student\'s *t*-test with Prism v.5.0 (GraphPad Software, Inc., La Jolla, CA, USA). *P*-values \<0.05 were considered to indicate a statistically significant difference. *n* indicates the number of mice analyzed for each genotype.
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![Influence and deletion of a conditional *Bim*^*fl*^ allele in mice. (**a**) Lysates from splenocytes from wt, floxed *Bim* (*Bim*^*fl/fl*^) and BIM-deficient mice (*Bim*^*fl/fl*^*/del*) were immunoblotted for BIM. Probing for *β*-actin served as a loading control. *N*=2 mice per genotype were tested, six independent experiments were performed. (**b**) White blood cell counts and (**c**) spleen weights from wt, *Bim*^*fl/fl*^ and *Bim*^*fl/fl*^*/del* mice were determined. *N*=5--6 mice for each genotype. Data represent mean±S.E.M. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 (paired *t*-test). (**d**) Thymocytes from mice of the indicated genotypes were isolated and single-cell suspensions stained with anti-CD4-PE (clone\# YTA3.2.1) and anti-CD8-FITC (clone\# 53.6.7.2). Dead cells were excluded from analysis by staining with 10 *μ*g/ml propidium iodide (PI; Sigma-Aldrich)](cddis2014409f1){#fig1}

![Induced *Bim*^*fl*^ deletion in adult mice. (**a**) *Bim*^*fl/fl*^*/Vav-CreER-tg* and control mice were treated for 5 days and (**b**) *Bim*^*fl/fl*^*/Rosa-CreER-tg* and control mice were treated three times within 5 days (1 day break in between dosing) with a daily dose of 4.8 mg Tamoxifen (4-OHT; Sigma) by oral gavage and then left untreated for 1 month or 3 weeks, respectively. Each FACS plot is representative of *N*\>3 repeat experiments](cddis2014409f2){#fig2}

![Induced deletion of *Bim*^*fl*^ in mature animals leads to increased WBC numbers and abnormalities in the composition of thymocyte subpopulations. Blood from (**a**) *Bim*^*fl/fl*^*/Vav-CreER-tg* and control mice as well as from (**b**) *Bim*^*fl/fl*^*/Rosa-CreER-tg* and control mice was analyzed with an ADVIA blood analyzer after the animals had been treated with 4-OHT, as described in [Figure 2](#fig2){ref-type="fig"}. (**c**) Thymocytes of mice of the indicated genotypes from **a** and **b** were stained with anti-CD4-PE and anti-CD8-FITC and analyzed by flow cytometry. *N*=4--8 mice for each genotype. Data represent mean±S.E.M. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 (paired *t*-test)](cddis2014409f3){#fig3}

![Induced deletion of *Bim*^*fl*^ in adult animals renders thymocytes resistant to BIM-dependent apoptotic stimuli. Thymocytes from 4-OHT-treated *Bim*^*fl/fl*^*/Vav-CreER-tg*, *Bim*^*fl/fl*^*/Rosa-CreER-tg* and control mice were cultured (**a**) in medium only, or were (**b**) treated with 1 *μ*g/ml Ionomycin (Sigma) or (**c**) with 2 ng/ml PMA (Sigma). At the indicated time points, the percentages of live cells were determined by staining with AnnexinV/PI (AnnexinV-PI=living cells). *N*=3--7 mice for each genotype. Data represent mean±S.E.M. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001 (paired *t*-test)](cddis2014409f4){#fig4}
